Eprex

Eprex Indications/Uses

epoetin alfa

Manufacturer:

Janssen-Cilag

Distributor:

DKSH
Full Prescribing Info
Indications/Uses
Epoetin alfa is indicated for the treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and peritoneal dialysis.
Epoetin alfa is indicated for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.
Epoetin alfa is indicated for the treatment of anaemia and reduction of transfusion requirements in adult cancer patients (with non-myeloid malignancies) receiving chemotherapy.
Epoetin alfa is indicated for the treatment of anaemia in adult HIV infected patients being treated with zidovudine having endogenous erythropoietin levels ≤500 mU/ml.
Epoetin alfa is indicated in adults to facilitate autologous blood collection within a predeposit programme and decrease the risk of receiving allogeneic blood transfusions in patients with moderate anaemia [haematocrits of 33-39%, haemoglobin of 10-13 g/dL, (6.2-8.1 mmol/l), no iron deficiency], who are scheduled for major elective surgery and are expected to require more blood than that which can be obtained through autologous blood collection techniques in the absence of Epoetin alfa. Treatment should only be given to patients if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).
Epoetin alfa is indicated to augment erythropoiesis in the perisurgical period in order to reduce allogeneic blood transfusions and correct postoperative anaemia in adult non-iron deficient patients undergoing major elective orthopaedic surgery. Use should be restricted to patients with moderate anaemia (eg Hb 10-13 g/dL) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml).
Epoetin Alfa is indicated for the treatment of anemia in patients with Low or Intermediate 1-risk Myelodysplastic Syndrome (MDS). MDS patients considered for therapy should have a hemoglobin less than 10 g/dl.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in